New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants

Data in JAMA show Menveo may provide infants protection against four of the most common meningococcal serogroups - A, C, W-135 and Y

11-Jan-2008

Menveo(TM) (MenACWY-CRM), a vaccine in development by Novartis, may protect infants using a schedule beginning at two months of age against four of the most common causes of meningococcal disease. According to the company, Menveo is the only meningococcal vaccine shown to generate protection against a broad range of serogroups in infants, potentially filling a large unmet medical need.

New data, published in the Journal of the American Medical Association, show that Menveo was well-tolerated and generated high levels of immunogenicity in infants against meningococcal serogroups A, C, W-135 and Y with a standard infant vaccination dosing schedule.

Infants have the highest rate of meningococcal disease, a potentially deadly bacterial infection. However, no currently available quadrivalent vaccine including Menomune® and Menactra® has demonstrated a strong and lasting immune response for this age group.

These new results build on numerous other clinical trial findings, which support that Menveo generates a strong immune response across all age groups. Novartis plans regulatory submissions for Menveo in the European Union and the United States in 2008.

Menveo is currently in multiple Phase III clinical trials involving infants, young children, adolescents and adults. It is based on the same technical expertise Novartis used to produce Menjugate®, a meningococcal serogroup C conjugate vaccine approved outside the United States since 2000 for use in individuals from two months old through adulthood.

The polysaccharide conjugation technique used to produce MenACWY-CRM improves immunization responses compared to older polysaccharide vaccines, which are poorly immunogenic in infants. Currently the only conjugate vaccines approved and available for use in infants protect only against serogroup C; these serogroup C vaccines are not approved in the United States. Menveo will therefore provide the opportunity to protect infants against a broad range of serogroups that cause meningococcal disease.

https://www.bionity.com/en/news/76408/new-data-show-menveo-to-be-the-first-quadrivalent-meningococcal-vaccine-to-provide-immunogenicity-in-infants.html